GW Pharmaceuticals’ Sativex (THC and cannabidiol) oral spray has received regulatory approval in Austria as a treatment of spasticity due to Multiple Sclerosis (MS).

The launch of Sativex in Austria is expected during 2012, following completion of the national pricing and reimbursement process. Sativex will be marketed in Austria by GW's marketing partner, Almirall.

In addition, the request to expand Sativex to additional European countries has been validated and is now under technical review by regulatory authorities in Belgium, Finland, Iceland, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal and Slovakia. This process is expected to be complete by mid-2012.

Sativex is also in phase III clinical development as a treatment for cancer pain.